《药品管理法实施条例》发布，23年来首次全面修订！

Core Viewpoint - The State Council of China has announced a comprehensive revision of the Drug Administration Law Implementation Regulations, which will take effect on May 15, 2026, marking the first major overhaul in over 20 years [1] Group 1: Regulatory Changes - The revised regulations will shift the focus from managing drug production and distribution to emphasizing the responsibilities of drug marketing authorization holders, enhancing the supervision of the entire drug lifecycle [4][5] - The revision includes a significant update, with over 90% of the clauses modified, reflecting the changes in drug research, production, distribution, and usage since the original regulations were enacted in 2002 [1][4] Group 2: Encouragement of Innovation - The new regulations explicitly support the research and development of new drugs based on clinical value, aiming to improve the quality and efficacy of generic drugs [5][6] - Four expedited pathways for drug approval, including breakthrough therapy drugs and conditional approvals, have been formally included in the regulations to accelerate the market entry of urgently needed medications [7][9] Group 3: Intellectual Property Protection - The revised regulations enhance the protection of drug intellectual property rights by introducing a drug trial data protection system and a market exclusivity period for innovative drugs [12][16] - Specific market exclusivity periods have been established for pediatric drugs (up to 2 years) and orphan drugs (up to 7 years), aligning with international practices [14][16] Group 4: Online Drug Sales Regulation - The new regulations impose clear responsibilities on online drug sales platforms, requiring them to establish dedicated management systems to oversee drug transactions and ensure compliance with safety standards [17][18] - The regulations also encourage the implementation of quality management standards for traditional Chinese medicine (TCM) production, aiming to enhance the quality of TCM materials [18] Group 5: Production Flexibility - The regulations allow for segmented contract manufacturing of drugs, which is particularly beneficial for innovative drugs that require specialized production techniques [19][20] - A pilot program for segmented production will begin in 2024, focusing on innovative biological products and urgently needed clinical products to improve production efficiency [20]